{
  "drug_id": "D007",
  "drug_name": "Glucomet",
  "indication": "Metabolic-D",
  "modality": "small molecule",
  "mechanism": "bispecific immune modulator",
  "moa_short": "Engages two targets to rebalance immune signaling.",
  "formulation": "tablet",
  "route": "oral",
  "regimen": "150 mg BID",
  "trial_id": "AMGN-D007-201",
  "phase": "Phase 2",
  "arms": [
    {
      "name": "Glucomet 150 mg BID",
      "n": 168,
      "dose": "150 mg BID"
    },
    {
      "name": "Placebo",
      "n": 139,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Metabolic-D with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Change from baseline in Symptom Score at Week 12",
    "endpoint_secondary": "Durable response at Week 24",
    "primary_effect": "LS mean difference -1.37 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.018522917146641726,
    "primary_ci": "[-1.77, -0.97]",
    "secondary_effect": "Did not meet prespecified significance threshold",
    "discontinuation_rate_pct": 10.438594306728483
  },
  "safety": {
    "common_ae": [
      [
        "Arthralgia",
        12.186591438703637
      ],
      [
        "Elevated ALT",
        10.950842969633943
      ],
      [
        "Diarrhea",
        9.631723643400758
      ],
      [
        "Headache",
        8.169591409090415
      ],
      [
        "Nausea",
        5.353654013999701
      ],
      [
        "Rash",
        4.6480320489138265
      ]
    ],
    "serious_ae_rate_pct": 5.095076753420004,
    "discontinuation_ae_rate_pct": 2.7689201197662947,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.9",
  "doc_date": "2025-12-26"
}